AbbVie Inc. ABBV announced that it has submitted regulatory applications to the FDA and the European Medicines Agency (EMA), seeking approval for its JAK inhibitor, Rinvoq (upadacitinib), for a new indication. The company is seeking approval for once-daily Rinvoq (15 mg) for treating adult patients with giant cell arteritis (GCA), an autoimmune disease-causing inflammation of the large arteries. The regulatory filings for GCA were based on data from the phase III SELECT-GCA study, which evaluated the safety and efficacy of Rinvoq in GCA patients. Data from the SELECT-GCA study showed that 46% of the GCA patients treated with Rinvoq plus 26-week steroid taper regimen achieved the primary endpoint of sustained remission (absence of GCA signs and symptoms) from week 12 through week 52 versus 29% of patients administered placebo with a 52-week steroid taper regimen. The study also met its key secondary endpoints, with 37% of patients in the Rinvoq arm achieving sustained complete remission compared to 16% of patients in the placebo arm. Shares of AbbVie have gained 9.9% so far this year compared with the industry’s growth of 24.2%. Zacks Investment Research Image Source: Zacks Investment Research Rinvoq, a JAK inhibitor, was initially approved in 2019 to treat moderate-to-severe rheumatoid arthritis (RA). Apart from RA, the drug is also approved for psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, Crohn’s disease and ulcerative colitis. Last month, ABBV launched Rinvoq, as a tablet and oral solution, in the United States for pediatric patients, two years and older, with polyarticular juvenile idiopathic arthritis and psoriatic arthritis who had an inadequate response or intolerance to one or more tumor necrosis factor blockers. These are the first pediatric indications for Rinvoq, which is now approved for eight indications across immune-mediated inflammatory diseases. Label-expanding studies evaluating Rinvoq in several immune-mediated diseases, including GCA, systemic lupus erythematosus, hidradenitis suppurativa vitiligo and takayasu arteritis, are ongoing. Rinvoq is a key top-line driver for AbbVie. The drug generated sales of $1.09 billion in the first quarter of 2024, which was up 61.9% year over year, owing to continuous label expansions of the drug to include new patient populations. Rinvoq and AbbVie’s other inflammatory disease drug, Skyrizi, are performing extremely well, bolstered by approvals in new indications. The drugs have the potential to replace revenues lost from blockbuster drug Humira, which started facing generic erosion in the United States in early 2023. Skyrizi and Rinvoq are expected to collectively exceed the peak revenues achieved by Humira by 2027. AbbVie expects the combined sales (risk-adjusted) of Skyrizi and Rinvoq to be more than $27 billion by 2027. Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. ACRV, Adaptive Biotechnologies Corporation ADPT and RAPT Therapeutics, Inc. RAPT, each holding a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Acrivon Therapeutics’ 2024 loss per share have narrowed from $3.05 to $2.47. Loss per share estimates for 2025 have narrowed from $3.04 to $2.55. Year to date, ACRV’s shares have rallied 51.4%. ACRV’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, the average surprise being 3.56%. In the past 60 days, estimates for Adaptive Biotechnologies’ 2024 loss per share have narrowed from $1.30 to $1.29, while loss per share estimates for 2025 have narrowed from $1.08 to $1.02. Year to date, ADPT’s shares have declined 18.3%. ADPT’s earnings beat estimates in two of the trailing four quarters, meeting the same once and missing on the remaining occasion, the average surprise being 0.65%. In the past 60 days, estimates for RAPT Therapeutics’ 2024 loss per share have narrowed from $2.94 to $2.93. Loss per share estimates for 2025 have narrowed from $2.06 to $2.05. Year to date, RAPT’s shares have declined 86%. RAPT’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 3.19%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV):Free Stock Analysis Report Adaptive Biotechnologies Corporation (ADPT):Free Stock Analysis Report Rapt Therapeutics (RAPT):Free Stock Analysis Report Acrivon Therapeutics, Inc. (ACRV):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...